1
Androgen depletion therapy (ADT) is the standard treatment to manage castration-resistant prostate cancer 2 (CRPC) [1] . Androgen receptor (AR) signaling changes; by gaining mutations and overexpressing to support 3 growth, as the cancer becomes castration resistant. In all phases of prostate cancer AR remains active and is 4 still expressed in patients undergoing ADT [2] [3] [4] . Mutated AR often can bypass the need for androgen activation, 5
and can act as transcriptional activator in absence of androgens, promoting tumor growth [5] . Several new 6 approaches are clinically available to block AR signaling one of them being blocking non-gonadal androgen 7 synthesis [6] . Another useful approach is to disrupt tubulin dependent AR translocation to nucleus. Nonetheless, 8 eventually the AR bypasses these strategies, leading to CRPC. It is highly therapeutically relevant to identify any 9 additional mechanism to block AR nuclear translocation [7] [8] [9] . 10
Our previous work shows that CYP3A5 has a critical role in AR signaling as it promotes AR nuclear translocation 11 and downstream signaling promoting growth [10] . CYP3A5 is a cytochrome P450 enzyme primarily expressed 12 in liver and small intestine. In liver, its main function is to process xenobiotics. CYP3A5 along with CYP3A4 13 metabolizes 50% of the commonly prescribed drugs [11] ; these drugs are inducers, inhibitors and substrates of 14 CYP3A enzymes. Apart from liver and small intestine CYP3A5 is also expressed in prostate where its normal 15 function is to convert testosterone to its lesser active derivative, 6β-hydroxytestosterone [12] . Prostate cancer 16 patients are typically elderly as the average age at diagnosis is 66 [13] and often suffer from comorbidities. 17
Medications prescribed for these comorbidities can be inducers, inhibitors or substrates of CYP3A5 and hence 18 can modify intratumoral CYP3A5 activity and alter AR signaling and response to ADT. Prior reports strongly 19 support our hypothesis that therapeutic management of cancers is compromised by drug-induced expression of 20 members of the CYP3A subfamily [14] . CYP3A5 is the main isoform expressed in prostate where as CYP3A4 is 21 the most common isoform expressed in liver. Although CYP3A4 and CYP3A5 share 80% similarity they are 22 differentially regulated [14] [15] [16] . CYP3A5 expressed in prostate is also differently regulated compared to the one 23 expressed in liver as it has a 5' UTR with androgen response elements (ARE). 24
Healthy prostate tissues are shown to express high basal levels of CYP3A5, but CYP3A5 expression in prostate 25 cancer tissues is less well-characterized [17] [18] [19] . Different expression patterns in tumor cells may be due to 26 polymorphic expression of CYP3A5. CYP3A5 has several variations most common being the CYP3A5*3, that 27 1 Dharmacon (Thermo scientific). MTS cell titer reagent was from Promega (Madison,WI). 2 Western blotting: Cells were washed in phosphate buffer (PBS) and lysed in RIPA buffer (50 mM TIRS, 150 3 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 2mM EDTA, 2mM EGTA) supplemented with 4 protease and phosphatase inhibitors. GAPDH was used as an internal control for total protein, tubulin for 5 cytoplasmic fraction and Lamin A/C for nuclear fraction. Infrared fluorescent-labeled secondary antibodies were 6 used for detection using Odyssey CLx. 7
Cell fractionation: Nuclear and cytoplasmic cell fractionation was prepared using NE-PER Nuclear and 8 cytoplasmic extraction kit from Thermo Scientific (Cat no.78833) and manufacturer's instructions were followed. 9
The cells were treated with drugs in charcoal-stripped phenol red free media 48 hours after plating. Drugs and 10 DHT were added at specified concentration and duration as indicated. Cells were washed in PBS once before 11 cells were suspended in CER buffer. Protease, phosphatase inhibitors and EDTA was added prior to cell lysis. 12
The pellet remaining after cytoplasmic isolation was washed twice with PBS. The pellet was suspended in NER 13 buffer for nuclear fraction extraction according to guidelines, samples were stored at -80ºC until further 14 processing. Tubulin and Lamin were used as internal controls for cytoplasmic and nuclear fractions respectively. 15 siRNA inhibition: Cells were plated in complete media without antibiotics on poly D-lysine-coated plates (80,000 16 cells per 6 well). After 48 hrs. of growth the cells were transfected using RNAimax according to the 17 manufacturer's instructions. The smart pool non-target (NT) siRNA (Dharmacon catalog# D-001810-10) was 18 used as a transfection control with the experimental target gene siRNAs. A pool of four siRNA (Dharmacon 19 catalog# L-009684-01) against the CYP3A5 were used to block the expression. The final concentration of the 20 siRNA (NT and targets) used was 30 nM. The cells were fixed in 4% paraformaldehyde for 20 minutes and permeabilized using permeabilizing buffer 23 (0.2% Tween 20 in PBS) for 5 minutes. Cells were blocked using 10% goat serum diluted in permeabilizing buffer 24 with 1% BSA for 15 minutes. Primary antibodies were diluted at 1:100 in staining buffer (1% BSA in PBS) and 25 incubated for 60 minutes at room temperature. Cells were washed three times (10 minutes each) in PBS. 26 Secondary antibodies, Cy 5 -conjugated Donkey Anti-rabbit (711-175-152) and Alexa Fluor 488 -conjugated 27 1 staning buffer and incubated for 30 minutes at room temperature. Cells were washed three times (10 minutes) 2 in PBS and stained with 1 µg/mL DAPI (4', 6-diamidino-2-phenylindole) in PBS for 5 minutes at room 3 temperature. The cells were stored in PBS at 4°C until imaging is completed. 4
Cells were imaged using confocal laser scanning microscopy on a Nikon A1R using a galvano scanner and a 5 60× Apo-TIRF oil immersion objective. To excite DAPI, FITC, TRITC and CY 5 405 nm, 488 nm, 561 nm and 638 6 nm solid-state lasers were used respectively. FITC and TRITC emissions were collected using GaAsP detectors 7 on the A1R+ microscope. NIS Elements software form Nikon was used for recording the data. 8 RT2 profiler: RNA was isolated using RNeasy Mini kit (Cat no.74104) from Qiagen (Germantown, MD) 9 manufacturer's instructions were followed. cDNA synthesis was performed using RT 2 first strand kit (Cat 10 no.330404) Qiagen, according to manufacturer's instructions. The cDNA was diluted and used as template to 11 analyze for gene expression pattern using RT² Profiler PCR Arrays (Cat no. 330231) specifically designed to 12 probe panel of Human Androgen Receptor Signaling Targets (PAHS-142Z). The real-time PCR reaction data 13 was collected using ABI 7500 fast real-time PCR system. A total of 96 genes were profiled, data analysis was 14 done using Geneglobe portal on Qiagen website. Samples (triplicates) were grouped into control (Non-Target) 15
and test (CYP3A5 siRNA) and normalized with Beta-2-microglobulin (B2M) and Ribosomal protein, large, P0 16 (RPLP). A set of genes were identified based on fold change cutoff value of 2.0 and p value of 0.005. 17
Luciferase assay: Cignal Lenti AR Reporter (luc) from Qiagen (product n0. 336851, Cat no. CLS-8019L) was 18 used to generate AR pathway sensing LNCaP and MDAPCa2b cell lines for the study of the AR signal 19 transduction pathway. These lentivirus particles have androgen response elements (ARE) fused to luciferase, 20 which detects any changes in AR downstream signaling. Cells were transfected according to manufacturer 21 instructions. Negative Control (only TATA box in place of ARE) transfected cell lines were also generated to 22 measure background luciferase activity. Cells were maintained under puromycin selection pressure to select for 23 stable chromosomal integration of the lentiviral constructs. The selected cells were tested for AR signaling 24 pathway activation in response to DHT treatment after drug treatment using Brightglo luciferase assay from 25
Promega (Cat no.E264A). The cells were collected into Eppendorf tube and divided into two equal aliquots. One 26 aliquot was used for luciferase assay and was lysed with Glolysis buffer (Cat no. E266A) and the second aliquot 1 was lysed with RIPA buffer for protein quantification. Americans (NHWA-LNCaP, C4-2, 22RV1, E006aahT) origin to determine their CYP3A5 polymorphism. (Table  14 1). Genotyping revealed that all the NHWA lines carry the *3/*3 CYP3A5 variant in homozygous form. The three 15 cell lines from AA origin, carry *1/*3 heterozygous wild type/mutant CYP3A5. E006aahT has been found to be 16 not of African American origin [22] and carries *3/*3 homozygous mutation. We used LNCaP (*3/*3) and 17
MDAPCa2b (*1/*3) cells for our current study as they are of NHWA and AA origin respectively, and are AR 18 positive commercially available (ATCC) and show similar response to androgens. 19 20
CYP3A5siRNA downregulates AR nuclear translocation in MDAPCa2b cells expressing wild type 21

CYP3A5 (*1/*3). To test if wild type full length CYP3A5 regulates AR nuclear activation in a similar fashion we 22
used MDAPCa2b cells, which express wild type CYP3A5 (*1/*3). MDAPCa2b cells were treated with NT and 23 CYP3A5 siRNA pool to specifically block CYP3A5 and then induced with DHT in charcoal stripped phenol red 24 free media to monitor AR nuclear translocation and activation. Cells were then stained with AR and Cy5 labelled 25 secondary antibody. CYP3A5 siRNA treatment resulted in decreased nuclear translocation of AR ( Fig. 1A ). This induction as compared to non-target siRNA pool treated cells. In the NT siRNA treated group we observed 4 significant cytoplasmic surge which was absent in the CYP3A5 siRNA treated cells. Of note CYP3A5 siRNA 5 treatment did not affect total AR protein expression ( Fig 1B) . Table 2 with fold changes greater than 2.0 and p-values less than 0.005 depicted ( Fig. 1D ). 12
Western analysis was performed to evaluate whether gene expression changes translated into changes in 13 protein expression. FKBP5, c-Myc, ELK-1, prostein protein expression also decreased in response to CYP3A5 14 siRNA treatment ( Fig. 1E1 ) consistent with mRNA downregulation (fold change 0.68, 0.55, 0.49 and 0.45 15 respectively, P value ≤ 0.05). We did not observe changes in the levels of MME, SPDEF and KLK2 protein levels 16 with CYP3A5 siRNA treatment ( Fig. 1E2 ). 17 18
Commonly co-prescribed CYP3A5 inducers /inhibitors can alter AR nuclear translocation. 19
The average age at detection is 66 for prostate cancer patients; hence, they often have comorbidities, and are 20 prescribed other medications to treat these co-morbidities while undergoing androgen deprivation treatment 21 (ADT). CYP3A5 is known to process 33% of the commonly prescribed drugs and these co-prescribed drugs can 22 be inducer/inhibitor of CYP3A5. Since AR is central to prostate cancer progression and is a main therapeutic 23 target in treating prostate cancer any alteration in AR signaling can alter efficacy of these regimens. Based on 24 our observation that CYP3A5 alters AR activity we wanted to test the effect of CYP3A5 inducers/inhibitors drugs 25 on AR signaling as CYP3A5 can be modulated by these co-prescribed drugs. To evaluate the effect of known 26 CYP3A inducers and inhibitors on AR nuclear translocation and downstream signaling we used two CYP3A 27 inhibitors, amiodarone (5 µM) and ritonavir (35 µM); and two inducers, phenytoin (50 µM) and rifampicin (30 1 µg/mL) [23] . Amiodarone is often prescribed as an anti-arrhythmic drug whereas ritonavir is a component of 2 highly active anti-retroviral therapy used in treating HIV patients. Phenytoin is one of the widely prescribed 3 antiepileptic drugs and rifampicin is a known CYP3A5 inducer. CYP3A5 is not the main target of any of these 4 drugs but its activity can be significantly modulated by these drugs. We tested their ability to affect AR activation 5 process due to their ability to modulate CYP3A5 expression, which is separate from their primary target. 6
Azamulin, a specific CYP3A inhibitor has been used as a control. 7 8 We tested the effect of these CYP3A5 inhibitors and inducers on total AR expression. Total cell lysates prepared 9 from LNCaP and MDAPca2b cells incubated with the selected drugs were analyzed by western blotting to verify 10 if protein expression of AR is affected. None of the drugs tested affects total AR protein expression in LNCaP 11
and MDAPCa2b cells except ritonavir ( Fig. 2A) . cells. We confirmed the CYP3A5 modulating effect of these drugs on AR activation by performing cell 20 fractionation studies with and without DHT induction. 21
Nuclear AR is decreased in LNCaP and MDAPCa2b cells treated with amiodarone compared to control cells that 23 did not receive drug treatment ( do not show increased nuclear AR in contrast to NT control (Fig. 2D ). This result supports that the observed 8 changes in AR nuclear fraction is dependent on the modulation of CYP3A5 by the above mentioned CYP3A5 9 inducers (rifampicin and phenytoin) and is independent of their effect on main primary target. amiodarone and chloramphenicol) (less AR activation) ( Fig 3A) . LNCaP cells showed increased luciferase 2 activity after treatment with CYP3A5 inducers phenytoin and rifampicin with DHT treatment, phenytoin shows an 3 increase in AR activity even without DHT induction similar to earlier observation ( Fig 3B) . The inhibitors 4 amiodarone and ritonavir show reduced luciferase units (AR activity) both with or without DHT induction ( Fig 3B) . Our previous work shows that CYP3A5 inhibition can lead to growth inhibition in LNCaP cells due to blocking of 20 AR activation and downstream signaling. In keeping with previously published results for LNCaP, the 21
MDAPCa2b, which carries one copy of wild type CYP3A5 (*1), also promotes AR nuclear localization. 22
MDAPCa2b cells showed reduced AR nuclear localization after CYP3A5 siRNA (pool) treatment as compared 23
to NT (pool). CYP3A5 is polymorphic with the wild type variant encoding full length translated protein being 24 expressed in 73% of AAs, whereas only 5% of this variant is expressed in NHWA [20, 24]. Since *3 is the most 25 common difference between AA and NHWA we analyzed the available prostate cancer cell lines and used one 26 (*3/*3, LNCaP) and the other (*1/*3, MDAPCa2b) cell line for this study. There are 12 known SNPs in the 27 on the SNPs. The most commonly expressed mutation (*3) is a point mutation at 6986A > G that results in 2 alternative splicing of an insertion from intron 3 resulting in a nonsense-mutated nonfunctional truncated protein. 3
Even though A>G mutation leads to truncated protein in *3 mutation, 5% of the matured RNA can bypass the 4 alternative splicing and express low levels of full length CYP3A5 protein as observed in LNCaP cells (*3/*3). The 5 most common SNP (*3) mutation is present in 95% of NHWA, whereas 75% of AA carry wild type and 10-13% 6 of AAs carry *6 and *7 mutations (truncated protein) [25, 26] . Prevalent expression of wild type CYP3A5 (*1/*1) 7 form can promote AR activation in the AA prostate cancer patients as compared to NHWA. Since CYP3A5 is the 8 major extrahepatic CYP3A isoform expressed in prostate and regulates AR activation, the presence of these 9
SNPs in CYP3A5 may alter prostate cancer occurrence growth and treatment resistance in a race dependent 10 manner. 11
12
Since MDAPCa2b carries a wt CYP3A5 we used this cell line for the PCR based pathway array to study the 13 effect of CYP3A5 inhibition on AR downstream signaling. All the genes in this q-PCR base array carry androgen 14 response elements and hence regulated by AR. The 11 genes which show maximum fold change (≥ 2.5) with 15 CYP3A5 siRNA treatment are known to play important role in prostate cancer growth and severity. Further 16 investigation revealed that four (SLC45A3, FKBP5, c-MYC and ELL2) of those 11 genes show reduced protein 17 expression whereas MME, SPDEF and KLK2 did not show fold changes in protein expression. SLC45A3 also 18 known as prostein is down regulated (-4.56 fold) with CYP3A5 siRNA treatment and belongs to solute carrier 19 family 45. Protein expression is seen in both normal and malignant prostate tissue, its messenger RNA and 20 protein are upregulated in response to androgen treatment in prostate cancer cells. [27, 28] . FKBP5 21 (downregulated, -4.43 fold, also called FKBP51) is a co-chaperone that belongs to a family of immunophilins, 22
FK506 binding proteins (FKBPs). FKBP5 works with several different signaling pathways, including steroid 23 receptor signaling, NF-kB, and AKT pathways, all of which contribute to tumorigenesis and drug resistance [29, 24 30] and FKBP5 is a target for AR signaling [31] . A recent study uncovered a mechanism in which FKBP5 is found 25
to form a complex with HSP90 and promote AR signaling in prostate cancer [32] . Members of this family are 26 targets for drugs such as rapamycin and cyclosporine. FKBP5 is known to modulate steroid receptor (androgen, 27 progesterone, glucocorticoid) function by forming complex with HSP90 and HSP70. c-MYC also significantly 1 downregulated with CYP3A5 siRNA treatment is one of the key genes amplified in prostate cancer progression. indicates that ELL2 has important role in DNA damage response and repair. This enables ELL2 loss to function 10 like a double edge sword where on one hand can induce prostate carcinogenesis and on the other can sensitize 11 cells to radiation therapy [42] . Human kallikrein-related peptidase 2 (KLK2, previously known as hK2) is a 12 secreted serine protease from the same gene family as PSA. It shares 80% sequence homology with PSA and 13 is responsible for cleavage of pre-PSA to active mature PSA [43] . Our studies only indicate fold change in mRNA 14 levels but not protein levels after CYP3A5 siRNA treatment. Studies give contradictory evidence towards KLK2's 15 use as marker for detection of prostate cancer in combination with PSA [44-46]. KLK2 has been found to 16 modulate AR to increase cell growth after development of CRPC [47] . In conclusion, this data supports our earlier 17 observation that CYP3A5 plays a major role in AR regulation thus modulating AR downstream signaling and 18 prostate cancer growth. This also points how presence of a wild type CYP3A5 (preferentially present in AAs) can 19 significantly alter AR signaling compared to cells carrying only inactive CYP3A5 polymorphic forms (expressed 20 in NHWAs). 21
CYP3A5 is an enzyme whose activity can be physiologically altered by many drugs that are activators or 22 inhibitors of CYP3A5. Men with prostate cancer undergoing ADT are often elderly and have comorbidities 23 requiring concomitant prescription medications, many of which are CYP3A5 inducers or inhibitors. The 24 modulation of CYP3A5 by concomitant drugs may enhance or interfere with ADT, of great relevance to the 25 AAs expressing wild type CYP3A5. Our data show that commonly prescribed CYP3A5 inducers promote AR 26 nuclear migration whereas CYP3A5 inhibitors block AR nuclear migration. In our current study, we have used 27 two CYP3A5 inhibitors (ritonavir and amiodarone) and two inducers (phenytoin and rifampicin) to test their effect 1 on AR activation and downstream signaling in both LNCaP and MDAPCa2b cell lines. The results of the study 2 indicate that the CYP3A5 inhibitors show less nuclear AR and less PSA expression similar to CYP3A5 siRNA. 3
Whereas, the inducers on the other hand promoted nuclear AR translocation with and without DHT induction. 4
Both the cell lines show similar effect since both the cell lines have different AR and CYP3A5 expression we 5
were not able to derive a quantitative difference between both the cell lines. The reporter assay also showed 6 similar response, which contains androgen response elements (AREs) to test the effect on AR downstream 7 signaling. Although CYP3A5 is not the main target of any of these drugs it was shown that the specific effect on 8 AR signaling is due to the changes in CYP3A5 and not due to the primary target of these drugs ( Figure 2D ).These 9 drugs inhibit both CYP3A4 and CYP3A5 isoform. Since CYP3A5 is the major extrahepatic form expressed in 10 prostate, the observed effect on AR signaling is due to the alteration in CYP3A5 and not CYP3A4. 11
Both the inducers increase the proliferation of the cells (LNCaP and MDAPCa2b) and the inhibitors reduce cell 12 growth. Interestingly the effect of inducers and inhibitors on growth are more pronounced in MDAPCa2b which 13 carries the wild type CYP3A5 as compared to LNCaP(*3/*3), with the exception of ritonavir. The observed 14 difference can be because the other three tested inhibitors only effect the AR nuclear localization whereas 15 ritonavir also affects total AR levels. Nonetheless, these data strongly suggest that concomitant CYP3A5 inhibitor 16 / inducers taken while the patient is undergoing ADT may alter the efficacy of ADT. Although drug interactions 17 monitor direct interactions between drugs the effect of concomitant CYP3A5 inducers and inhibitors have not 18 been demonstrated previously. Based on our data we suggest that taking CYP3A5 inhibitors concomitantly may 19 clinically benefit patients undergoing ADT (enhancing its effect), whereas taking CYP3A5 inducers may reduce 20 the efficacy of the ADT treatment (countering its effect). These observations suggest that the effect of these 21 inhibitors and inducers may be more relevant in AA patient as they tend to carry the wild type CYP3A5 and may 22 result in therapeutic resistance. This study also suggests care be taken while prescribing CYP3A5 inducers when 23 the patients are undergoing ADT. In addition, it also suggests that genetic testing for CYP3A5 polymorphism in 24 patients may provide significant information about the potential impact of these interactions, facilitating 25 personalized treatment regimens. responsive prostate cell lines were tested for presence of wild type (*1) or mutant inactive (*3) CYP3A5 3 polymorphism by using a qPCR based genotyping assay. 4 MDAPCa2b cells that were treated with CYP3A inhibitors (Ritonavir-35 µM and Amiodarone-5 µM) and inducers 1 (Phenytoin-50 µM and Rifampicin-30µg/ml) for 48 hours in charcoal stripped serum media followed by with and 2 without DHT induction (90min for LNCaP or 120 min for MDAPCa2b). Nucleus is stained with DAPI (blue), AR 3 is stained with Cy5-secondary (red) antibody. Scale bar represents 25 µm. A section from center of z-stack is 4
shown here to demonstrate the localization of AR in nucleus after treatments. 
